Patent Term Adjustment Versus Double Patenting

25 February 2016 PharmaPatents Blog

In Magna Electronics, Inc. v. TRW Automotive Holdings Corp., No. 1:12-cv-654; 1:13-cv-324 (Dec. 10, 2015), Judge Maloney of the U.S. District Court for the Western District of Michigan granted TRW’s motion for partial summary judgement of invalidity based on obviousness-type double patenting over a later-granted child patent. While it was only a matter of time before the Federal Circuit decision in Gilead was applied in this manner, these circumstances raise important issues that should be given separate consideration. Since Magna and TRW have settled this litigation, we will have to wait for another case to determine whether parent-child obviousness-type double patenting can obliterate Patent Term Adjustment.

The Patent At Issue

The patent at issue was Magna’s U.S. Patent 7,339,149 which was filed November 16, 1999 with a priority claim to February 26, 1993, and issued March 4, 2008, after an interference proceeding. The patent was awarded 498 days of Patent Term Adjustment based on the interference.

The cited patent was U.S. Patent 7,402,786, filed October 6, 2006 as a continuation of the ‘149 patent. The ‘786 patent issued July 22, 2008 with 63 days of Patent Term Adjustment, but expired February 26, 2013 (twenty years from the priority date of the ‘149 patent) because of a Terminal Disclaimer over U.S. Patent 7,388,182, which was a grandchild of the ‘149 patent that did not earn any Patent Term Adjustment.

Thus, the challenged patent was a parent patent that had earned Patent Term Adjustment, while the cited patent was its later-granted child patent with a twenty-year term.

The Gilead Decision

The district court cited the Federal Circuit decision in Gilead Sciences, Inc. v. Natco Pharma Limited, for the principle that the later-granted ‘182 patent could be cited as an obviousness-type double patenting reference against the ‘149 patent. As explained in this article, in Gilead the Federal Circuit determined that “a patent that issues after but expires before another patent can qualify as a double patenting reference for that other patent.” Although the Federal Circuit qualified its holding as applying “under the circumstances of this case,” the district court did not address the possibility that a parent-child scenario amounted to different circumstances.

The End Of Patent Term Adjustment?

Parent patents often experience a longer examination process, and may earn considerable Patent Term Adjustment if they are granted after a successful appeal of an examiner’s rejection to the Patent Trial and Appeal Board. On the other hand, a parent patent may have narrower claims than a subsequently granted child patent, and may recite a species (e.g., lead compound, approved product, or commercial embodiment) that is anticipated by a genus claimed in the child patent. Thus, if a child patent can be cited against its parent, it often may be difficult to distinguish the claims on the merits.

But the patents at issue in Gilead were not parent-child patents. Thus, a parent-child scenario may not be “under the circumstances” presented in Gilead. One important issue that was not addressed in Gilead is whether the judicially-created doctrine of obviousness-type double patenting can (or should) take precedence over the statutory grant of Patent Term Adjustment.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

RCE PTA Carve-Out Resumes After Interference
18 September 2019
PharmaPatents
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
DHS Moves Closer to Launching its H-1B Cap Registration System
16 September 2019
Labor & Employment Law Perspectives
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.